Literature DB >> 17825438

Heterogeneity in motoneuron disease.

Diether Lambrechts1, Wim Robberecht, Peter Carmeliet.   

Abstract

Recently, mutations in several genes have been identified as primary causes for the degeneration of motoneurons and their axons. Strikingly, mutations in the same genes were associated with clinically different motoneuron syndromes. The identity of these genes also shed light on the mechanisms of motoneuron degeneration and revealed that overlapping motoneuron phenotypes might be caused by heterogeneous molecular mechanisms. Overall, these findings have challenged the diagnostic classification system set by clinical judgement and triggered the notion of heterogeneity in motoneuron disease. It will now be especially relevant to identify the mechanisms and principles that motoneuron diseases have in common, as this will allow us to identify the most relevant therapeutic targets. On the other hand, heterogeneity in motoneuron disease also implies that finding a monotherapy cure for motoneuron disease will be challenging and that pre-clinical testing of therapeutic targets should not be limited to a single animal model.

Entities:  

Mesh:

Year:  2007        PMID: 17825438     DOI: 10.1016/j.tins.2007.07.002

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  9 in total

Review 1.  Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease.

Authors:  Jeffrey Rosenfeld; Michael J Strong
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 2.  The application of biomarkers in clinical trials for motor neuron disease.

Authors:  Jeban Ganesalingam; Robert Bowser
Journal:  Biomark Med       Date:  2010-04       Impact factor: 2.851

3.  Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration.

Authors:  Koen Poesen; Diether Lambrechts; Philip Van Damme; Joke Dhondt; Florian Bender; Nicolas Frank; Elke Bogaert; Bart Claes; Line Heylen; An Verheyen; Katrien Raes; Marc Tjwa; Ulf Eriksson; Masabumi Shibuya; Rony Nuydens; Ludo Van Den Bosch; Theo Meert; Rudi D'Hooge; Michael Sendtner; Wim Robberecht; Peter Carmeliet
Journal:  J Neurosci       Date:  2008-10-15       Impact factor: 6.167

4.  Establishing a novel knock-in mouse line for studying neuronal cytoplasmic dynein under normal and pathologic conditions.

Authors:  Jun Zhang; Alison E Twelvetrees; Jacob E Lazarus; Kiev R Blasier; Xuanli Yao; Nirja A Inamdar; Erika L F Holzbaur; K Kevin Pfister; Xin Xiang
Journal:  Cytoskeleton (Hoboken)       Date:  2013-03-21

5.  Deficits in axonal transport precede ALS symptoms in vivo.

Authors:  Lynsey G Bilsland; Erik Sahai; Gavin Kelly; Matthew Golding; Linda Greensmith; Giampietro Schiavo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

6.  A Population Proportion approach for ranking differentially expressed genes.

Authors:  Mugdha Gadgil
Journal:  BMC Bioinformatics       Date:  2008-09-18       Impact factor: 3.169

Review 7.  Kynurenine Pathway Metabolites as Biomarkers for Amyotrophic Lateral Sclerosis.

Authors:  Vanessa X Tan; Gilles J Guillemin
Journal:  Front Neurosci       Date:  2019-09-20       Impact factor: 4.677

8.  Latent cluster analysis of ALS phenotypes identifies prognostically differing groups.

Authors:  Jeban Ganesalingam; Daniel Stahl; Lokesh Wijesekera; Clare Galtrey; Christopher E Shaw; P Nigel Leigh; Ammar Al-Chalabi
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

9.  A conditioning lesion provides selective protection in a rat model of Amyotrophic Lateral Sclerosis.

Authors:  Colin K Franz; Eric T Quach; Christina A Krudy; Thais Federici; Michele A Kliem; Brooke R Snyder; Bethwel Raore; Nicholas M Boulis
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.